The medication is commonly used across conditions presenting with systemic or localized discomfort. It plays a role in addressing symptoms related to systemic imbalance following menopause. It is applied across domains where additional symptomatic support is needed, providing support that helps ease the overall symptom burden and may assist with maintaining functional stability.

---

Symptom Management and Functional Support

Menorest (Tibolone) is relevant for easing symptoms that create noticeable physiological strain and interfere with daily functioning. This includes managing symptom clusters that may become intense or disruptive, such as symptoms related to heightened physiological activity and symptoms linked to organ-specific functional stress. The medication is commonly used during phases of increased distress, where short-term symptomatic assistance is appropriate. It supports the patient during difficult episodes by easing distress and helps them cope more steadily with symptom fluctuations.

---

“The support provided may assist with maintaining functional stability when symptom clusters become disruptive or temporarily overwhelming.”

Quick Fact: Context: Systemic Discomfort

Menorest (Tibolone) is officially defined by regulatory bodies as a treatment intended for postmenopausal women, and use should generally begin at least 12 months after the last natural menstrual period. The medicine is contraindicated, meaning it must not be used, in several populations due to explicit regulatory restrictions.

Absolute contraindications include a history of breast cancer or other oestrogen-dependent malignant tumours, undiagnosed genital bleeding, and untreated endometrial hyperplasia. The medicine is also prohibited for patients with a current or past history of venous thromboembolism (VTE) or arterial thromboembolic disease (e.g., stroke or heart attack), and those with acute liver disease or impaired liver function that has not returned to normal.

For pregnancy and lactation, the medicine is contraindicated and must be withdrawn immediately if pregnancy occurs. Pediatric and adolescent use is not applicable as the medicine is indicated for women only.

Specific conditions such as endometriosis, uterine fibroids (leiomyoma), hypertension, and epilepsy require close supervision during use, as stipulated in the official prescribing information.

Interactions with other medicines and products — official regulatory information for Menorest (Tibolone)

---

Interaction Scope

Category	Information (Strictly Regulatory Statement)
Medicinal product categories with documented interactions	Oral Anticoagulants; Cytochrome P450 3A4 (CYP3A4) Inducers.
Specific interacting medicines	Warfarin and other coumarin derivatives; Rifampicin; Carbamazepine; Phenytoin; St John's Wort (Hypericum perforatum).
Mechanistic basis of interactions	Enzyme Induction of CYP450 leads to increased metabolism of Tibolone; Pharmacodynamic enhancement of anticoagulant effect.
Timing-based interaction rules	No mandatory time separation is required for co-administered drugs.
Population-specific interaction notes	Women already receiving anticoagulant treatment require a careful assessment due to the risk of enhanced anticoagulant effect.

---

Interaction Classifications (High-Level)

Category	Classification / Statement (Strictly Regulatory)
Interaction severity classification	Classified as requiring caution or close supervision/monitoring.
Interaction-context constraints	Co-administration with coumarin-type anticoagulants is a condition that requires monitoring of coagulation parameters.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with CYP3A4-inducing products (e.g., Rifampicin, Carbamazepine) results in the increased metabolism of Tibolone, which reduces the systemic concentration of its active compounds and may reduce its effectiveness.
• The use of Tibolone may enhance the activity of coumarin-type oral anticoagulants, necessitating the monitoring of coagulation parameters.
• The herbal product St John's Wort is documented to potentially reduce the effectiveness of Tibolone.

Connection to the overall interaction profile (2–4 sentences): Official regulatory documents define the product's interaction profile by identifying substances that affect its concentration through pharmacokinetic changes (via enzyme induction) and substances that affect its action through pharmacodynamic reinforcement (anticoagulants). These documented interaction patterns establish the requirement for the monitoring of coagulation status when co-administered with anticoagulants and note the reduced efficacy constraint when combined with CYP inducers.

The mechanism of Menorest (Tibolone) is uniquely defined by its role as an inactive pro-drug that is rapidly metabolized into three different active substances, which together act as a Selective Tissue Estrogenic Activity Regulator (STEAR).

Multi-Receptor Agonism via Active Metabolites

This domain covers how the drug's three active metabolites target and activate the Estrogen Receptor (ER), Progesterone Receptor (PR), and Androgen Receptor (AR) simultaneously. The activation of these core steroid receptors initiates distinct, fundamental signaling pathways initiating specific gene transcription in various hormone-responsive systems.

Tissue-Specific Enzyme and Signaling Balance

This domain addresses the sophisticated tissue selectivity achieved by influencing local enzymes like Sulfatase (STS) and Sulfotransferase (SULT). This regulation strategically reduces the availability of active estrogenic metabolites in sensitive areas like the uterine lining, with estrogenic effects functionally expressed systemically without promoting proliferation-associated cellular signaling locally, resulting in a functional balance of hormonal signaling.

Dual Central and Peripheral Pathway Modulation

This domain focuses on the mechanistic cascade linking receptor activation to system-level physiological control. Estrogenic metabolites activate receptors in the Central Nervous System (CNS) to modulate hypothalamic signaling for thermoregulation, while concurrent activation in bone tissue modulates the cellular pathways that influence the processes that regulate osteoclast activity.

How to Use Menorest (Tibolone)

Menorest (Tibolone) is used according to a standardized, non-adjustable regimen. The administration is limited to the oral route as a 2.5 mg tablet, taken once daily. This medicine is for continuous, uninterrupted use, meaning the tablet is taken every day without a break or cyclical schedule.

Administration Protocol

The established dosage for adults is fixed at one 2.5 mg tablet per day. The tablet is to be swallowed whole with some water and should not be crushed or chewed. For maximum consistency, the tablet should be taken preferably at the same time every day. The time of day and whether it is taken with food or on an empty stomach does not affect the administration.

Starting Treatment: Treatment initiation generally occurs at least 12 months after a woman’s last natural menstrual bleed. The standard 2.5 mg dose is also used in older adults, as no age-specific dose adjustment is necessary.

Handling a Missed Dose: If a daily dose is forgotten, the missed tablet is taken as soon as it is remembered, unless it is more than 12 hours overdue. If the dose is missed by more than 12 hours, the forgotten tablet is skipped entirely, and the continuous regimen is resumed by taking the next dose at the usual time. A double dose must not be taken to compensate for the skipped dose.

Research evidence / Overview of Studies for Menorest (Tibolone)

This section provides a summary of the clinical studies and systematic reviews used by regulators to evaluate Menorest (Tibolone), focusing on the types of trials, populations, and outcomes studied. The research described here helps show what has been observed so far but does not determine whether an individual will respond similarly.

---

Evidence for Symptom Relief in Postmenopausal Women

The research evidence examined for this medicine is derived from Randomized Controlled Trials (RCTs). These short-term and intermediate-term studies were applied in research contexts involving fluctuating or unstable symptoms and were used in studies examining symptom intensity or variability. Specifically, research examined patient-reported outcomes describing perceived discomfort, such as hot flushes and night sweats, along with overall menopausal symptom scores.

Studies reported measurements of change in the frequency and severity of vasomotor symptoms compared to the baseline condition. Systematic reviews consolidated data, describing patterns related to the change in hot flushes and also in measures of urogenital comfort. The data for certain groups remain insufficient, and research provides context but not individual predictions.

---

Evidence for Bone Health and Density

The evidence base for bone health is built from both Randomized Controlled Trials (RCTs), which measured changes in Bone Mineral Density (BMD) over one to two years, and larger-scale, long-term trials that examined the incidence of fractures. This research examined outcomes related to systemic or functional imbalance that is associated with fragile bones, focusing on populations including recently postmenopausal women as well as older women with existing bone thinning.

Studies reported measurements of change in Bone Mineral Density (BMD) at key sites like the hip and spine. The largest fracture trials described measurements of the incidence of vertebral and non-vertebral fractures over the observation period. The full long-term profile of fracture risk management beyond the duration of the major dedicated trials is not fully established, and the research is ongoing.

---

What Remains Uncertain in the Clinical Research

Inconsistent results were observed across different smaller RCTs focusing on specific endpoints, such as sexual function. The certainty remains low for this specific outcome, and evidence quality varies across studies. A key limitation is that comparative evidence is lacking against all other standard treatment options for every outcome. Furthermore, while research exploring short-term symptom changes is extensive, the long-term effects are not fully established for every aspect, such as whether ongoing use is necessary to observe sustained effects.

Key Studies & References

1. Effect of Tibolone on Bone Mineral Density in Postmenopausal Women: Systematic Review and Meta-Analysis
2. Tibolone: benefit-risk balance (UK regulatory guidance)
3. NICE guideline NG23: Menopause: identification and management (Used for clinical context/gaps)

Common questions about Menorest (Tibolone) (FAQ)

Q: What is the main difference between Menorest and traditional hormone replacement therapy (HRT)?

A: Official product information classifies Menorest as a Selective Tissue Estrogenic Activity Regulator (STEAR). Unlike some traditional HRT, Menorest functions as a pro-drug, meaning it is metabolized in the body into three active compounds. These compounds collectively provide estrogenic, progestogenic, and androgenic effects in different tissues.

Q: Do I need to take a progestogen with Menorest?

A: Regulatory documents state that a separate progestogen should not be added when taking the standardized 2.5 mg tablet. This is because the medicine is designed to provide specific progestogenic effects, making additional progestogen unnecessary for its intended use.

Q: Can Menorest be used by women who have had a hysterectomy?

A: Official guidelines state that women who have undergone surgical menopause, such as a hysterectomy, may begin treatment immediately. As with any prescription medicine, the start of treatment is dependent upon a review of the individual's full medical history.

Q: Is it normal to experience spotting or bleeding while on Menorest?

A: Vaginal bleeding or spotting is listed as a Common side effect in regulatory documents. This irregular bleeding may be observed during the initial three to six months of treatment, and regulatory information indicates it often resolves spontaneously.

Q: Does Menorest (Tibolone) affect weight?

A: Official regulatory documents list weight increase as a Common side effect. This means it is an effect reported to occur in ge 1 in 100 women using the medicine.

Q: Can Menorest be used long-term?

A: Official documents note that the risks of certain safety signals, such as breast and endometrial cancer, increase with the duration of use. The decision to continue treatment long-term is not fixed and is based on an individual assessment of risks and benefits.

Q: Why do doctors recommend stopping Menorest after a certain period of time?

A: Regulatory guidelines suggest using the lowest effective dose for the shortest duration necessary to manage symptoms. This caution is partly based on evidence that the risk of stroke increases substantially in postmenopausal women aged 60 years and older.

Q: What does the term 'tissue-specific' mean in relation to Menorest?

A: The medicine is classified as a Selective Tissue Estrogenic Activity Regulator (STEAR). This means its active compounds are metabolized to exert different hormonal effects—estrogenic, progestogenic, or androgenic—depending on the specific tissue they target in the body.

Q: Is Menorest prescribed for symptoms other than hot flashes?

A: Official documents state the medicine is indicated for the treatment of estrogen deficiency symptoms in postmenopausal women. It is also indicated for the prevention of osteoporosis in women considered at high risk of future fractures.

Q: How long does it typically take to notice the effects of Menorest?

A: Regulatory-cited research has examined changes in menopausal symptom scores after 12 weeks of use. Personal expectations regarding response timing are best discussed with a healthcare provider.

Q: Can Menorest help with mood swings during menopause?

A: Clinical data reviewed by regulatory authorities suggests the medicine may exert positive effects on mood. Improvements on psychological scales have been observed in some studies that examined symptom relief.

Q: What are the most commonly reported side effects when starting Menorest?

A: The side effects officially classified as Common are the most frequently reported. Irregular bleeding, for example, is a Common side effect that is often observed during the initial three to six months of treatment.

Q: How often do I need follow-up appointments when using Menorest?

A: Regulatory information emphasizes the need for close supervision for certain existing conditions. Official documents also note that ongoing monitoring of parameters such as coagulation status, endometrial thickness, and breast density should be considered during treatment.

Q: Does Menorest affect cholesterol or lipid levels?

A: Regulatory-cited research has shown that treatment with this medicine lowers levels of High-Density Lipoprotein (HDL) cholesterol.

Q: What research evidence supports the use of Menorest for post-menopausal symptoms?

A: Regulatory documents cite randomized controlled trials (RCTs) indicating that the standardized 2.5 mg dose of Tibolone was described in the trial context as being more effective than placebo in relieving the frequency of vasomotor symptoms, such as hot flushes.

Q: What is the expected duration of treatment with Menorest?

A: Official guidelines state that the lowest effective dose should be used for the shortest duration necessary to meet treatment goals. The total treatment length is not fixed and is based on an individual assessment of risks and benefits.

Q: Are there any known drug interactions between Menorest and common thyroid medications?

A: Official regulatory interaction summaries for this medicine do not list common thyroid medications as substances that require specific caution or monitoring during co-administration.

Q: Is Menorest available in different strengths?

A: The standardized dosage described in regulatory documents for Menorest is fixed at a 2.5 mg tablet. The administration protocol specifies taking one of these tablets once daily.

Q: Does Menorest (Tibolone) have a risk of breast tenderness?

A: Regulatory documents list breast tenderness as a Common side effect, meaning it is a documented risk of use. Common effects occur in ge 1 in 100 women.

Q: Does Menorest cause hair loss or hair growth?

A: Regulatory documents list abnormal hair growth (hirsutism) as a Common side effect of this medicine. Hair loss is not listed among the classified Common, Uncommon, or Rare adverse reactions in the official product information.

Q: What are the signs that Menorest is starting to work?

A: Regulatory-cited research measures the medicine’s effect by tracking a reduction in the frequency and severity of vasomotor symptoms, such as hot flushes and night sweats. Patients often perceive this reduction as the medicine starting to work.

Q: Is it necessary to have a bone density scan before starting Menorest?

A: The medicine is indicated for preventing osteoporosis in women at high risk of future fractures. Official documents require a full individual risk assessment before starting treatment, but they do not list a bone density scan as a mandatory prerequisite for all patients.

Q: Can Menorest (Tibolone) cause stomach upset or nausea?

A: Regulatory documents and high-level summaries sometimes include stomach upset or nausea as possible effects. These gastrointestinal issues are generally mild.

Q: Can I switch from a different HRT to Menorest?

A: Official regulatory documents provide specific instructions for switching to Menorest from both sequential hormone replacement therapy (HRT) preparations and continuous-combined HRT preparations.

Q: What is the recommended initial course of treatment with Menorest?

A: The recommended daily dosage is one 2.5 mg tablet, taken continuously. Official guidelines emphasize that the medicine should be used for the shortest duration necessary at the lowest effective dose.

Official Storage and Disposal Requirements

The storage and disposal instructions for Menorest (Tibolone) are explicitly defined in official regulatory documents to ensure the product's stability and proper environmental handling.

Item	Requirement based on Official Regulatory Documentation
Storage Temperature	Store below 30 C
Environmental Protection	Protect from light and moisture
Packaging	Keep in the original container
Child Safety	Keep out of the sight and reach of children
Disposal Method	Dispose of unused product according to local regulations

Storage constraints mandate maintaining the product below 30 C and protecting it from environmental degradation by keeping it sealed in the original packaging. This guarantees the medicine's stability until its expiration date. For disposal, regulatory documents explicitly require users to avoid discarding the tablets in household waste or wastewater, directing that disposal must be done in accordance with specific pharmaceutical waste collection procedures.